Drugs / LVRNA009
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05364047 | Jul 2021 → Oct 2022 | COVID-19 | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05352867 | Mar → Jun 2022 | COVID-19 | AIM Vaccine Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05428592 | Apr → Oct 2023 | Orthocoronavirinae infectious disease | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05682638 | Jan 2023 → Dec 2024 | COVID-19 | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVRNA009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05364047 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 mRNA Vaccine (LVRNA009)” NCT05352867 ↗ |